Retrospective analysis of the effectiveness of a pediatric protocol BFM90 in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia

VernacularTitle:儿童方案BFM90治疗费城染色体阴性成年人急性淋巴细胞白血病
Author: Lihui PENG ; Dengming HU ; Sanbin WANG
Publication Type:Journal Article
Keywords: Philadelphia chromosome-negative; Leukemia,lymphocytic,acute; Adult; Antineoplastic combined chemotherapy protocols
From: Journal of Leukemia & Lymphoma 2010;19(6):331-333,337
CountryChina
Language:Chinese
Abstract: Objective To retrospectively analyze the efficacy of a pediatric treatment protocol,BFM90,in adult patients with acute lymphobiastic leukemia (ALL) up to the age of 60 years. Methods From August 2004 to October 2007,60 adult patients (median age,40 years; range,18 to 60 years) with Philadelphia chromosome-negative ALL were treated with the BFM90 protocol. Clinical effect were historically compared with that of the 35 patients (median age,42 years; range,18 to 56 years) who were treated with Hyper-CVAD protocol. Results At 42 months,complete remission (CR) rate,event-free survival (EFS) and overall survival (OS) rates were 93 % (56 patients),60 % (36 patients) and 65 % (39 patients),respectively.Age is an important prognostic factor,with 45 years of age as best cutoff. CR (P=0.02),OS (P ＜0.001),and EFS (P ＜0.001) of BFM90 were compared superiorly with that of the previous Hyper-CVAD experience.Conclusion These results suggest that pediatric protocol superior to the outcome of adult patients with Philadelphia chromosome-negative ALL.